Page last updated: 2024-08-24

fradafiban and Bleeding

fradafiban has been researched along with Bleeding in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akkerhuis, KM; Baardman, T; Deckers, JW; Hoffmann, J; Peels, HO; Simoons, ML; Stibbe, J; Suryapranata, H; van Den Brand, MJ; van Der Wieken, LR; van Der Zwaan, C	1

Trials

1 trial(s) available for fradafiban and Bleeding

Article	Year
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart (British Cardiac Society), 2001, Volume: 85, Issue:4 Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Area Under Curve; Biphenyl Compounds; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Hemostasis; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Pyrrolidines; Risk	2001

Article

Year

Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.

Heart (British Cardiac Society), 2001, Volume: 85, Issue:4

Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Area Under Curve; Biphenyl Compounds; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Hemostasis; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Pyrrolidines; Risk

2001